Manipulating dendritic cell biology for the active immunotherapy of cancer
Top Cited Papers
- 15 October 2004
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 104 (8) , 2235-2246
- https://doi.org/10.1182/blood-2003-12-4392
Abstract
Dendritic cells (DCs) are specialized antigen-presenting cells (APCs) that have an unequaled capacity to initiate primary immune responses, including tolerogenic responses. Because of the importance of DCs in the induction and control of immunity, an understanding of their biology is central to the development of potent immunotherapies for cancer, chronic infections, autoimmune disease, and induction of transplantation tolerance. This review discusses recent advances in DC research and the application of this knowledge toward new strategies for the clinical manipulation of DCs for cancer immunotherapy.Keywords
This publication has 155 references indexed in Scilit:
- Cross-priming of CD8+ T cells stimulated by virus-induced type I interferonNature Immunology, 2003
- Molecular identification of a danger signal that alerts the immune system to dying cellsNature, 2003
- Selective imprinting of gut-homing T cells by Peyer's patch dendritic cellsNature, 2003
- BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1Nature Immunology, 2003
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Blood Dendritic Cells Interact with Splenic Marginal Zone B Cells to Initiate T-Independent Immune ResponsesImmunity, 2002
- DCs induce CD40-independent immunoglobulin class switching through BLyS and APRILNature Immunology, 2002
- Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLPNature Immunology, 2002
- Mouse and human dendritic cell subtypesNature Reviews Immunology, 2002
- Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cellsNature Biotechnology, 2002